<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343172</url>
  </required_header>
  <id_info>
    <org_study_id>CHDM201X2103C</org_study_id>
    <nct_id>NCT02343172</nct_id>
  </id_info>
  <brief_title>Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma</brief_title>
  <official_title>A Phase Ib/II, Open-label, Multicenter Study of Oral HDM201 in Combination With Oral LEE011 in Adult Patients With Liposarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the MTD/RP2D of the HDM201 and LEE011 combination and evaluate whether the&#xD;
      combination is safe and has beneficial effects in patients with liposarcoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2015</start_date>
  <completion_date type="Actual">October 16, 2019</completion_date>
  <primary_completion_date type="Actual">October 16, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib: Incidence of Dose Limiting Toxicities (DLTs) during the first cycle of treatment.</measure>
    <time_frame>5 years</time_frame>
    <description>DLTs in the first cycle of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase Ib: Exposure to HDM201 and LEE011 as measured by AUC 0-24h</measure>
    <time_frame>5 years</time_frame>
    <description>as measured by AUC0-24h</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: Progression free survival (PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>To assess the preliminary anti-tumor activity of HDM201 in combination with LEE011 in liposarcoma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/II: Incidence and severity of AEs and SAEs</measure>
    <time_frame>5 years</time_frame>
    <description>Run-in part to assess safety of HDM201 in combination with LEE011</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/II: number of patients with dose interruptions and reduction</measure>
    <time_frame>5 years</time_frame>
    <description>Run-in part To assess tolerability of HDM201 in combination with LEE011</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/II: dose intensity</measure>
    <time_frame>5 years</time_frame>
    <description>Run-in part To assess tolerability of HDM201 in combination with LEE011</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/II: Pharmacokinetics (PK) parameters of HDM201 and LEE011: Cmax</measure>
    <time_frame>5 years</time_frame>
    <description>Run-in part to evaluate PK parameters of HDM201 and LEE011</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/II: Pharmacokinetics (PK) parameters of HDM201 and LEE011: Tmax</measure>
    <time_frame>5 years</time_frame>
    <description>Run-in part to evaluate the PK parameters of HDM201 and LEE011</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/II: Pharmacokinetics (PK) parameters of HDM201 and LEE011: AUClast</measure>
    <time_frame>5 years</time_frame>
    <description>Run-in part to evaluate the PK parameters of HDM201 and LEE011</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/II: Pharmacokinetics (PK) parameters of HDM201 and LEE011: AUCtau</measure>
    <time_frame>5 years</time_frame>
    <description>Run-in part to evaluate the PK parameters of HDM201 and LEE011</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/II: Changes from baseline of Pharmacodynamics (PD) markers in blood (GDF-15)</measure>
    <time_frame>5 years</time_frame>
    <description>Run-in part measure of GDF-15 fold-change in protein levels (PD direct targets of p53) to assess PD changes from baseline in blood and a potential relationship with clinical outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/II: Changes from baseline of Pharmacodynamics (PD) markers in tumor tissue (p21, MDM2)</measure>
    <time_frame>5 years</time_frame>
    <description>Run-in part measure of p21 and MDM2 protein levels by IHC (H-Score) (p53 and CDK4 pathways) to assess changes from baseline of PD markers in tumor tissue and a potential relationship with clinical outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib/II: anti-tumor activity endpoint (BOR, PFS)</measure>
    <time_frame>5 years</time_frame>
    <description>Run-in part to assess PD effect of HDM201 and LEE011 and a potential relationship with clinical outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: BOR, ORR and PFS as per RECIST v1.1, assessed by investigator</measure>
    <time_frame>5 years</time_frame>
    <description>Run-in part to assess the preliminary anti-tumor activity of HDM201 in combination with LEE011 in liposarcoma</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: BOR, ORR and PFS as per RECIST v1.1, assessed by investigator</measure>
    <time_frame>5 years</time_frame>
    <description>Run-in part to further assess the anti-tumor activity of HDM201 in combination with LEE011 in liposarcoma</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>Liposarcoma</condition>
  <arm_group>
    <arm_group_label>HDM201+LEE011</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDM201</intervention_name>
    <arm_group_label>HDM201+LEE011</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <arm_group_label>HDM201+LEE011</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically documented, locally advanced or metastatic WD/DD&#xD;
             liposarcoma who have received at least one prior systemic therapy&#xD;
&#xD;
          -  Patients with radiologic progression, defined by RECIST v.1.1, occurring while on/or&#xD;
             within 6 months after last systemic treatment, prior to enrollment&#xD;
&#xD;
          -  ECOG performance status of 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with compounds with the same mode of action&#xD;
&#xD;
          -  Patients with TP53 mutated tumors, if the molecular status is known&#xD;
&#xD;
          -  Symptomatic central nervous system metastases&#xD;
&#xD;
          -  Inadequate organ function&#xD;
&#xD;
          -  Previous and concomitant therapy that precludes enrollment, as defined by protocol&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lyon Cedex</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17708</url>
    <description>Results for CHDM201X2103C can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2015</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liposarcoma</keyword>
  <keyword>MDM2 inhibition</keyword>
  <keyword>cdk4 inhibition</keyword>
  <keyword>HDM201</keyword>
  <keyword>LEE011</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

